Invivyd Reports Positive Phase 3 LIBERTY Data for VYD2311
NEW HAVEN, Conn. — September 29, 202 Invivyd announced topline results from the Phase 3 LIBERTY study evaluating VYD2311,...
Phase 3
Advertisement
PolarityBio to Present Phase 3 SkinTE Data at SAWC Fall 2026
SALT LAKE CITY — September 29, 2026 PolarityBio announced that results from its pivotal Phase 3 COVER DFUS II...
Cellectar Reports Iopofosine I 131 Data in BTKi-Refractory Waldenström Macroglobulinemia
FLORHAM PARK, N.J. — September 29, 2026 Cellectar Biosciences announced that a subset analysis from the Phase 2 CLOVER-WaM...
Medicus Pharma Submits Optimized Teverelix Registrational Protocol to FDA
PHILADELPHIA — September 29, 2026 Medicus Pharma Ltd. announced that it has submitted an optimized seamless Phase 2b/3 registration-intent...
Verastem Reports Two-Year RAMP 201 Data in LGSOC
BOSTON — September 28, 2026 Verastem Oncology announced the publication in Gynecologic Oncology of two-year follow-up data from the...
Advertisements
Eccogene Receives $50M Milestone After Elecoglipron Phase 3 Start
BOSTON and SHANGHAI — September 28, 2026 Eccogene announced that it has received a $50 million milestone payment from...
HUTCHMED and AstraZeneca Submit US NDA for ORPATHYS Plus TAGRISSO
HONG KONG, SHANGHAI and FLORHAM PARK, N.J. — September 29, 2026 HUTCHMED (China) Limited announced that AstraZeneca has submitted...
Immuneering Presents Atebimetinib Pancreatic Cancer Data at AACR
NEW YORK — September 28, 2026 Immuneering Corporation presented new data at the 2026 AACR Conference on Pancreatic Cancer...
CervoMed Advances Neflamapimod With New Tablet and FDA Dose Flexibility
BOSTON — September 28, 2026 CervoMed Inc. announced pharmacokinetic, regulatory and manufacturing advances for neflamapimod, including a new 50...
Sagimet to Present 52-Week Denifanstat Data at KOL Event
FOSTER CITY, Calif. — September 28, 2026 Sagimet Biosciences Inc. announced that it will host a virtual key opinion...
Advertisement
